Twinbeech Capital LP Has $52.78 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Twinbeech Capital LP lifted its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 105.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 333,386 shares of the medical research company's stock after buying an additional 171,360 shares during the period. Natera makes up 0.9% of Twinbeech Capital LP's holdings, making the stock its 28th biggest position. Twinbeech Capital LP owned 0.25% of Natera worth $52,775,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. LRI Investments LLC purchased a new position in Natera during the fourth quarter worth about $29,000. Blue Trust Inc. raised its stake in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the period. EverSource Wealth Advisors LLC raised its stake in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares during the period. Principal Securities Inc. raised its stake in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its stake in Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after purchasing an additional 332 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Performance

NTRA stock traded up $0.84 during trading on Friday, hitting $153.32. 1,085,198 shares of the company's stock traded hands, compared to its average volume of 1,389,879. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 52 week low of $92.14 and a 52 week high of $183.00. The stock has a fifty day moving average price of $149.39 and a two-hundred day moving average price of $157.51. The stock has a market capitalization of $20.94 billion, a price-to-earnings ratio of -87.11 and a beta of 1.79.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company's quarterly revenue was up 36.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.56) earnings per share. As a group, equities analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. UBS Group lifted their target price on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Morgan Stanley boosted their price target on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. BTIG Research reissued a "buy" rating on shares of Natera in a research note on Friday, February 28th. Royal Bank of Canada began coverage on shares of Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target on the stock. Finally, Robert W. Baird boosted their price target on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Natera has an average rating of "Moderate Buy" and a consensus price target of $182.12.

Insider Buying and Selling at Natera

In related news, Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total value of $590,760.00. Following the transaction, the director now owns 9,704 shares in the company, valued at approximately $1,433,183.76. This represents a 29.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 6,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total value of $859,740.00. Following the transaction, the insider now owns 143,768 shares in the company, valued at approximately $20,600,516.72. This trade represents a 4.01% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 152,436 shares of company stock valued at $22,019,079. 7.60% of the stock is owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.